
    
      Approximately 350 adult subjects will be recruited from approximately 80 study centers in the
      United States, Canada, and Europe who were enrolled in the ASPEN-1 Study Protocol 1720302 and
      de novo subjects (not previously enrolled in ASPEN-1 Study Protocol 1720302) will be treated
      with up to 4 different doses of daxibotulinumtoxinA for injection.
    
  